These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10825563)

  • 21. Osmotic capsules: A universal oral, controlled-release drug delivery dosage form.
    Waterman KC; Goeken GS; Konagurthu S; Likar MD; MacDonald BC; Mahajan N; Swaminathan V
    J Control Release; 2011 Jun; 152(2):264-9. PubMed ID: 21315121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of push-pull osmotic tablets using chitosan-poly(acrylic acid) interpolymer complex as an osmopolymer.
    Ketjinda W; Sinchaipanid N; Limsuwan P; Leuenberger H; Mitrevej A
    AAPS PharmSciTech; 2011 Mar; 12(1):132-40. PubMed ID: 21181509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The delivery mechanism of micro-porous osmotic pump tablets].
    Zhao XL; Li Q; Gong XF; Li SM
    Yao Xue Xue Bao; 2007 Feb; 42(2):226-30. PubMed ID: 17518057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the tablet core factors influencing the release kinetics and the loadability of push-pull osmotic systems.
    Malaterre V; Ogorka J; Loggia N; Gurny R
    Drug Dev Ind Pharm; 2009 Apr; 35(4):433-9. PubMed ID: 18989838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of controlled release osmotic pump tablet of glipizide solid dispersion.
    Patel GC; Asodaria KV; Patel HP; Shah DR
    Curr Drug Deliv; 2014; 11(6):817-27. PubMed ID: 23859357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asymmetric membrane capsules for delivery of poorly water-soluble drugs by osmotic effects.
    Wang CY; Ho HO; Lin LH; Lin YK; Sheu MT
    Int J Pharm; 2005 Jun; 297(1-2):89-97. PubMed ID: 15885936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation design and characterization of an elementary osmotic pump tablet of flurbiprofen.
    Patel KN; Mehta TA
    PDA J Pharm Sci Technol; 2014; 68(4):333-46. PubMed ID: 25035256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and characterization of osmotic pump capsules containing polyoxyethylene and pH modifier to control the release of nifedipine.
    Yu J; Meng X; Dong X; Han M; Li G; Chen Y; Liu Y; Hu L
    Eur J Pharm Biopharm; 2021 Jun; 163():102-108. PubMed ID: 33819628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine. I. Cellulose acetate as a semipermeable membrane.
    Makhija SN; Vavia PR
    J Control Release; 2003 Apr; 89(1):5-18. PubMed ID: 12695059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel osmotic pump tablet using core of drug-resin complexes for time-controlled delivery system.
    Wang C; Chen F; Li JZ; Tang H; Li X; Yan KS; Ye GH; Pan WS
    Yakugaku Zasshi; 2008 May; 128(5):773-82. PubMed ID: 18451626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A controlled porosity osmotic pump system with biphasic release of theophylline.
    Bi Y; Mao S; Gan L; Li Y; Wang C; Xu N; Zheng Y; Cheng Q; Hou S
    Chem Pharm Bull (Tokyo); 2007 Nov; 55(11):1574-80. PubMed ID: 17978514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delivery of prazosin hydrochloride from osmotic pump system prepared by coating the core tablet with an indentation.
    Liu L; Wang J; Zhu S
    Drug Deliv; 2007 Apr; 14(4):219-24. PubMed ID: 17497354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo evaluation of controlled-release matrix tablets of highly water-soluble drug applying different mw polyethylene oxides (PEO) as retardants.
    Wen H; Li X; Li Y; Wang H; Wang Y; Wang T; Pan W; Yang X
    Drug Dev Ind Pharm; 2018 Apr; 44(4):544-552. PubMed ID: 29130753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissolution kinetics and physical characterization of three-layered tablet with poly(ethylene oxide) core matrix capped by Carbopol.
    Hong SI; Oh SY
    Int J Pharm; 2008 May; 356(1-2):121-9. PubMed ID: 18272308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and evaluation of osmotic pump-based controlled release system of Ambroxol Hydrochloride.
    Cheng X; Sun M; Gao Y; Cao F; Zhai G
    Pharm Dev Technol; 2011 Aug; 16(4):392-9. PubMed ID: 20429827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preparation and
    Li N; Fan L; Wu B; Dai G; Jiang C; Guo Y; Wang D
    Drug Dev Ind Pharm; 2019 Jul; 45(7):1079-1088. PubMed ID: 30909753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration.
    Anschütz M; Wonnemann M; Schug B; Toal C; Donath F; Pontius A; Pauli K; Brendel E; Blume H
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):158-70. PubMed ID: 20137768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Preparation of atenolol monolithic osmotic pump tablets].
    Liu LX; Che BJ; Xu Q
    Yao Xue Xue Bao; 2006 May; 41(5):457-60. PubMed ID: 16848324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benchtop-magnetic resonance imaging (BT-MRI) characterization of push-pull osmotic controlled release systems.
    Malaterre V; Metz H; Ogorka J; Gurny R; Loggia N; Mäder K
    J Control Release; 2009 Jan; 133(1):31-6. PubMed ID: 18840483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and optimization of buspirone oral osmotic pump tablet.
    Derakhshandeh K; Berenji MG
    Res Pharm Sci; 2014; 9(4):233-41. PubMed ID: 25657794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.